HIV / AIDS in the News

ACTG Evaluates Osteoporosis Treatment as Novel Approach Targeting the HIV Reservoir - POZ

 

AI, telehealth can ease communication about sexual health, HIV prevention - Yahoo

 

AI, telehealth can ease communication about sexual health, HIV prevention - KLAS 8 News Now

 

AI, telehealth can ease communication about sexual health, HIV prevention – KLAS - KLAS 8 News Now

 

FDA approves Gilead’s Bixlenvo, smallest single-tablet option for virologically suppressed HIV patients - Managed Healthcare Executive

 

What to Know from the FDA’s End of August Activity - PharmTech.com

 

FDA Approves Gilead's Bixlenvo, Smallest Once-Daily Single Tablet Regimen for HIV - Contagion Live

 

Former teacher charged with child sex crimes, HIV exposure released on bond - ABC Columbia

 

FDA Approves Gilead’s Bixlenvo, Once-Daily Pill for Virologically Suppressed Adults with HIV - Contract Pharma

 

FDA Approves Bixlenvo Once-Daily Single-Tablet Regimen for Virologically Suppressed Adults With HIV - Pharmacy Times

 

1,209 HIV-positive patients have undergone cardiac procedures at Jayadeva since 2013 - The Hindu

 

Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infection - TradingView

 

FDA Approves Lisraya for Adults with Dermatomyositis, Bixlenvo for Virologically Suppressed Adults with HIV, Mounjaro to Reduce MACE in Adults with Type 2 Diabetes - Pharmaceutical Executive

 

HIV Age Positively | Gilead - Gilead Sciences

 

Compound with the potential to treat drug-resistant HIV identified - Phys.org

 

Community gathers to fight HIV stigma in Shreveport - KTALnews.com

 

FDA Approves Bixlenvo, a Single Tablet Option for Adults With HIV - Drug Topics

 

FDA approved Gilead's new once-daily HIV pill for patients on complex regimens - qz.com

 

FDA approves Gilead’s Bixlenvo, a once-daily single tablet virologically suppressed adults with HIV - PharmaLive

 

Community gathers to fight HIV stigma in Shreveport - KTALnews.com

 

HIV Resistance Assay Offers Quick, Low-Cost Results for RTs - Medscape

 

Gilead’s Bixlenvo gains US approval - The Pharma Letter

 

Gilead once-daily HIV pill approved in U.S. (GILD:NASDAQ) - Seeking Alpha

 

The Trump administration is shifting funding for HIV prevention. Vulnerable Oklahomans could suffer - Tulsa Flyer

 

National Faith HIV/AIDS Awareness Day 2026 - POZ

 

FDA approves Gilead's Bixlenvo — smallest once-daily single-tablet HIV regimen - Dealroom

 

Philippines posts highest estimated adolescent HIV incidence in Asean - Inquirer.net

 

Bixlenvo Approved as Single-Tablet Option in HIV-1 Management - MPR - Medical Professionals Reference

 

HIV Advocates Are Among This Year’s Carr-Ryan Center for Human Rights Fellows - POZ

 

US FDA approves Gilead’s once-daily combination pill for HIV treatment - WTVB